Skip to main content

Table 1 Patient information

From: Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

N (%) Clinical trial Cohort Present study
Overall 50 (100) 44 (100)
Gender Male 36 (72) 31 (70.5)
Female 14 (28) 13 (29.5)
Age at diagnosis = < 65 15 (30) 14 (32)
>  65 35 (70) 30 (68)
MIPI Low risk 8 (16) 7 (16)
Medium risk 15 (30) 13 (29.5)
High risk 23 (46) 21 (47.7)
Missing 4 (8) 3 (6.8)
TP53 Wild-type 23 (46) 20 (45.5)
Deletions 17 (34) 14 (31.8)a
Mutated 11 (25) 11 (25)a
Missing 1 (2.3) 1 (2.3)
Ki-67 < 30% 17 (34) 12 (27)
> 30% 21 (42) 20 (46)
Missing 12 (24) 12 (27)
Overall Survival (months) Median 15.08 15.08
Number of deaths 20 18
Time to progression (months) Median 13.65 13.65
Number of deaths 24 21
Median Overall Survival (months) 15.08 15.08
Median Time to Progression (months) 13.65 13.65
  1. MIPI = Mantle Cell Lymphoma International Prognostic Index
  2. atwo patients had both TP53 deletion and mutation
\